Skip to main content
Fig. 2 | Journal of Neuroinflammation

Fig. 2

From: Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway

Fig. 2

Caspase-1 inhibitor ameliorated EAMG severity and decreased the expression of CD86 and MHC class II among OX62+DC in EAMG rats. The rats in Ac-YVAD-cmk treatment group exhibited lower clinical scores when compared with rats in EAMG group (**p < 0.01) (a). The serum was obtained on day 43 p.i. and anti-R97-116 IgG titer and affinity were determined (b). MNCs were isolated from the lymph nodes of rats in EAMG and Ac-YVAD-cmk groups. Expression of CD86 and MHC class II among OX62+DC were decreased in rats treated with Ac-YVAD-cmk compared to that in EAMG rats in vivo (*p < 0.05) (c)

Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094